-
-
Key words:
- fulminant myocarditis /
- development /
- diagnosis
-
-
[1] Inaba O,Satoh Y,Isobe M,et al.Factors and values at admission that predict a fulminant course of acute myocarditis:data from Tokyo CCU network database[J].Heart Vessels,2017,32(8):952-959.
[2] Ammirati E,Veronese G,Cipriani M,et al.Acute and Fulminant Myocarditis:a Pragmatic Clinical Approach to Diagnosis and Treatment[J].Current Cardiol Rep,2018,20:114.
[3] Blauwet LA,Cooper LT.Myocarditis[J].Progress Cardiovascular Dis,2010,52(4),274-288.
[4] Freedman SB,Haladyn JK,Floh A,et al.Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis[J].Science China Life Sciences,2018,62(2):187-202.
[5] Liu PP,Mason JW.Advances in the Understanding of Myocarditis[J].Circulation,2001,104(9):1076-1082.
[6] Shauer A,Gotsman I,Keren A,et al.Acute viral myocarditis:current concepts in diagnosis and treatment[J].Israel Med Association J,2013,15(3):180-185.
[7] Freedman SB,Haladyn JK,Floh A.Pediatric myocarditis:emergency department clinical findings and diagnostic evaluation[J].Pediatrics,2007,120(6):1278-1285.
[8] Miyake CY,Teele SA,Chen L,et al.In-Hospital Arrhythmia Development and Outcomes in Pediatric Patients With Acute Myocarditis[J].Am J Cardiol,2014,113(3):535-540.
[9] Lorena M,Ioan M.Diagnostic and prognostic values of B-type natriuretic peptides(BNP) and N-terminal fragment brain natriuretic peptides(NT-pro-BNP):review article[J].Cardiovascular J Africa,2013,24(7):286-289.
[10] 李朔朔,韩国鑫,靳红义,等.应激指标血生长分化因子-15、儿茶酚胺、热休克蛋白-70与急性冠脉综合征的相关性分析[J].中华急诊医学杂志,2018,27(10):1095-1100.
[11] Caforio ALP,Malipiero G,Marcolongo R,et al.Myocarditis:A Clinical Overview[J].Curr Cardiol Rep,2017,19(7):63.
[12] Punja M,Mark DG,Mccoy JV,et al.Electrocardiographic manifestations of cardiac infectious-inflammatory disorders[J].Am J Emerg Med,2010,28(3):364-377.
[13] Ginsberg F,Parrillo JE.Fulminant Myocarditis[J].Crit Care Clin,2013,29(3),465-483.
[14] Mendes LA,Dec GW,Picard MH,et al.Right ventricular dysfunction:an independent predictor of adverse outcome in patients with myocarditis[J].Am Heart J,1994,128(2):301-307.
[15] Maisch B,Ruppert V,Pankuweit S.Management of fulminant myocarditis:A diagnosis in search of its etiology but with therapeutic options[J].Current Heart Failure Rep,2014,11(2):166-177.
[16] Caforio ALP,Pankuweit S,Arbustini E,et al.Current state of knowledge on aetiology,diagnosis,management,and therapy of myocarditis:a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases[J].Europ Heart J,2013,34(33):2636-2648.
[17] Gannon MP,Schaub E,Grines CL,et al.State of the art:Evaluation and prognostication of myocarditis using cardiac MRI[J].J Magn Reson Imag,2019,49(7):e122-e131.
[18] Kindermann I,Kindermann M,Kandolf R,et al.Predictors of Outcome in Patients With Suspected Myocarditis[J].Circulation,2008,118(6):639-648.
[19] Leone O,Veinot JP,Angelini A,et al.2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology[J].Cardiovascular Pathol,2012,21(4):245-274.
[20] Verschure DO,Somsen GA,van Eck-Smit BL,et al.Tako-tsubo cardiomyopathy:How to understand possible pathophysiological mechanism and the role of I-123-MIBG imaging[J].J Nucl Cardiol,2014,21(4):730-738.
[21] Gori T,Anadol R.Tako-Tsubo syndrome,spontaneous coronary dissection and microvascular disease:Sex-differences[J].Clin Hemorheol Microcirc,2018,70(4):375-379.
[22] Wang YX,da Cunha V,Vincelette J,et al.Antiviral and myocyte protective effects of murine interferon-beta and -{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice[J].Am J Physiol Heart Circ Physiol,2007,293(1):H69-76.
[23] Horwitz MS,La Cava A,Fine C,et al.Pancreatic expression of interferon-γ protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis[J].Nature Med,2000,6(6):693-697.
[24] Okada I,Matsumori A,Matoba Y,et al.Combination treatment with ribavirin and interferon for coxsackievirus B3 replication[J].J Lab Clin Med,1992,120(4):569-573.
[25] Matsumori A,Crumpacker CS,Abelmann WH.Prevention of viral myocarditis with recombinant human leukocyte interferon α A/D in a murine model[J].J Am Coll Cardiol,1987,9(6):1320-1325.
[26] Rewa OG,Villeneuve PM,Lachance P,et al.Quality indicators of continuous renal replacement therapy(CRRT) care in critically ill patients:a systematic review[J].Int Care Med,2016,43(6):750-763.
[27] Rajagopal SK,Almond CS,Laussen PC,et al.Extracorporeal membrane oxygenation for the support of infants,children,and young adults with acute myocarditis:A review of the Extracorporeal Life Support Organization registry[J].Crit Care Med,2010,38(2):382-387.
[28] Nahum E,Dagan O,Lev A,et al.Favorable Outcome of Pediatric Fulminant Myocarditis Supported by Extracorporeal Membranous Oxygenation[J].Pediatr Cardiol,2010,31(7):1059-1063.
[29] Jones CB,Cassidy JV,Kirk R,et al.Successful Bridge to Recovery With 120 Days of Mechanical Support in an Infant With Myocarditis[J].J Heart Lung Transplant,2009,28(2):202-205.
[30] Zhong ZP,Wang H,Hou XT.Extracorporeal Membrane Oxygenation as a Bridge for Heart Failure and Cardiogenic Shock[J].Biomed Res Int,2016,2016:7263187.
[31] Zhang S.Sudden cardiac death in China:current status and future perspectives[J].Europace,2015,17(suppl 2):ii14-18.
-
计量
- 文章访问数: 408
- PDF下载数: 1986
- 施引文献: 0
下载: